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Abstract
Background: Peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2) is a transcription factor with a key
role in adipocyte differentiation, lipid storage and glucose homeostasis. The Ala allele of the common Pro12Ala
polymorphism in the isoform PPAR-γ2 is at the center of many controversies because in some populations, it has
been observed to be associated with T2DM or obesity but, not in others. The aim of this study was to investigate
the association of Pro12Ala polymorphism in the PPAR-γ2 gene with susceptibility to obesity or T2DM in a
Cameroonian population.
Methods: This case-control study included 62 obese, 60 T2DM patients and 120 controls (60 non obese and
60 patients without T2DM), all unrelated and of Cameroonian origin. PPAR-γ2 was examined by genotyping for
Pro12Ala using the Restriction Fragment Length Polymorphism - Polymerase Chain Reaction (PCR - RFLP).
Results: A portion of the 270 base pair bands of the PPAR-γ2 gene was successfully amplified. The Ala12 variant
was totally absent from the study population, all participants being homozygote Pro/Pro.
Conclusion: PPAR-γ2 Pro12Ala gene polymorphism may not be associated with obesity and T2DM. These results
suggest that, PPAR-γ2 is unlikely a major gene for obesity or T2DM in the study population.
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Background
Type 2 diabetes mellitus and obesity are a major global
health problem. The prevalence of obesity and T2DM is
increasing dramatically and WHO reports that more
than 500 million people are obese [1] and 387 million
have diabetes [2]. T2DM is a metabolic disease charac-
terized by hyperglycemia that can occur as a result of
impaired insulin secretion, insulin resistance in periph-
eral tissues and increased hepatic glucose output [3],
while obesity occurs as the result of chronic energy im-
balance involving physical inactivity, excessive energy in-
take, depression, sleep disorders and low socioeconomic
status [4]. Obesity and T2DM are called “multifactorial”
or “complex” diseases because, they depend on multiple
genetic factors as well as environment.
Some genes are thought to be involved in the devel-
opment of T2DM and obesity amongst which, the
peroxisome proliferator activated receptor gamma
(PPAR-γ) gene. PPAR-γ is a member of a subfamily of
the nuclear receptor superfamily of a ligand activated
transcription factors (PPAR) that consists of 3 sub-
types: PPAR-α, PPAR-β and PPAR-γ. PPARγ2 which
results from mRNA alternative splicing of PPAR-γ is
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expressed predominantly in the adipose tissue. It has been
shown that PPAR-γ has an important role in adipocyte
differentiation and that it regulates lipid metabolism
and sensitivity to insulin [5]. A CCA-GCA mutation
leading to the substitution of proline by alanine on
codon 12 of exon B of the PPAR-γ2 has been described.
This mutation was first identified by Schuldiner’s group
in 1997 with different ethnic population showing vari-
ous allelic frequencies that is probably modulated by en-
vironmental and other genetics factors. Caucasians have
the highest frequency (12 %), followed by Mexican Ameri-
cans (10 %), West Samoans (8 %), African Americans
(3 %), while Chinese have the lowest (1 %) [6]. In Africans
and Asians, frequency of Ala 12 is low (1–3 %). The Ala
isoform may lead to a less efficient stimulation of the
PPAR-γ target genes and predisposes to lower levels of
adipose tissue mass accumulation which in turn may be
responsible for improved insulin sensitivity [7]. The large
and increasing burden of non communicable diseases and
the potential for modifying risk through adequate treat-
ments and lifestyle alterations make the identification of
methods for early detection of persons at greater risk
an important public health challenge. Knowledge of
genetic polymorphisms that allow accurate quantifica-
tion of T2DM and obesity risk will allow the develop-
ment of complex models with diagnostic and
prognostic. Many studies clearly show heterogeneous ef-
fects of this polymorphism on predicting susceptibility to
the risk of T2DM and obesity in various populations [8–
10]. This preliminary study aimed to investigate the asso-




This is a case-control study involving 62 obese
adults and 60 non-obese controls, and 60 T2DM pa-
tients and 60 non-diabetic healthy controls of Cam-
eroonian origin, aged 20 years old and above. Obese
and T2DM patients were recruited from the out-
patient clinic of the National Obesity Center of the
Yaoundé Central Hospital, and non-obese controls
from the general population. For all participants,
data was collected on the sex and age; we measured
height, waist and hip circumference to the nearest
0.5 cm, and weight in light clothes to the nearest
0.1 kg, and we then calculated the body mass index
(BMI) as weight in kg/height2 in m2, and the waist-
to-hip ratio. Obesity was defined as a BMI ≥30 kg/
m2. We measured the resting blood pressures using
standardized procedures with an automatic sphygmoman-
ometer Omron HEM-705 CP (Omron Corporation, Tokyo,
Japan).
Biochemical assays
Fasting plasma glucose (glucose oxidase–peroxidase
method), serum cholesterol (cholesterol oxidase phenol4-
amino antipyrene peroxidase method), serum triglycerides
(glycerol phosphatase oxidase − phenol4-amino antipyrene
peroxidase method), and high-density lipoprotein (HDL)-
cholesterol (cholesterol oxidase phenol4-amino antipyrene
peroxidase method) were measured on a spectrophotom-
eter (UV Mini 1240) using Chronolab kits (Chronolab
Systems, Barcelona, Spain). Low-density lipoprotein
(LDL)-cholesterol was calculated using the Friedwald’s
formula [11].
DNA extraction and molecular genotyping
Genomic DNA was isolated from dried blood spots on
Whatmann filter paper by the chelex method [12]. The
Pro12Ala polymorphism of the PPARγ2 gene was analysed
using the Polymerase Chain Reaction-Restriction Fragment
Length Polymorphism (PCR-RFLP) method. Exon B was
amplified with a T3 Thermocycler (BIOMETRA) using
the forward primer: 5′-GCCAATTCAAGCCCAGTC-3′
and the reverse primer: 5′-GATATGTTTGCAGACAGT
GTATC-3′ (SIGMA-ALDRICH). Each PCR was performed
in a final volume of 15 μl containing 100 ng of DNA ex-
tract, 5 pmol of each primer, 100 μmol/L of each deoxynu-
cleotide triphosphate (dNTP), 0.5 U of Hot Star Taq DNA
polymerase (QIAGEN), 1.5 μl of PCR buffer with 1 mmol/
L of MgCl2 and 7.8 μl of nuclease free water. The reaction
was carried out under the following conditions: predena-
turation at 95 °C for 15 min, followed by 30 cycles of de-
naturation at 95 °C for 1 min, annealing at 56 °C for 1 min
and elongation at 72 °C for 1 min, and a final extension at
72 °C for 10 min. Electrophoresis was conducted to confirm
the 270 bp PCR products. Six microliters of positive PCR
products were then digested at 37 °C overnight with 0.2 μl
of the Bst UI restriction endonuclease using the New
England Buffer 4 recommended by the manufacturer
(NEW ENGLAND BIOLABS, UK). Digestion products
were analysed by electrophoresis using a 3 % agarose gel.
In order to verify whether our samples contained an en-
zyme inhibitor, we carried out a mix-in experiment using
the Tsp 5091 restriction endonuclease to digest the mix-
ture containing Pro12Ala amplicons and rs 12255372
amplicons with a restriction site for the Tsp 5091 enzyme.
Statistical analysis
Statistical analysis was performed using IBM SPSS for
Windows, version 20.0 (IBM Corp., Armonk New York,
USA). Quantitative variables were expressed as mean
(Standard deviation (SD). The clinical and laboratory
characteristics of cases and controls were compared using
chi-square tests. The continuous variables have been
studied by ANOVA T test, Mann Whitney U test. A p
value < 0.05 was considered statistically significant.
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Results
The biochemical and anthropometric results for the
study population are shown in Tables 1 and 2. In the
group of obese status (Table 1), fasting blood glucose
was significantly higher in obese subjects (p = 0.027), as
well as systolic blood pressure (p < 0.001) and diastolic
blood pressure (p < 0.001). Considering lipid profile, only
total cholesterol levels were significantly higher in obese
subjects compared to non-obese ones (p = 0.04). While,
in the group of T2DM status (Table 2), the diastolic
blood pressure (p =0.034), total Cholesterol (p < 0.001),
LDL - Cholesterol (p < 0.001) and the atherogenic index
(p < 0.001) were significantly higher in non T2DM patients
compared to the T2DM patients. The genotype analysis
revealed that a portion of the 270pb band of the PPAR-γ2
gene.Ala12 variant was totally absent from the study
population, all participants being homozygote Pro/Pro.
Discussion
Africa is experiencing a surge on obesity prevalence and
related morbidity and mortality within the context of
one of the most rapid epidemiological transition in the
world history [1, 2]. Obesity and T2DM are caused by
combined effect of many factors that could be environ-
mental, psychosocial and genetic. Although the epidemic
is attributable to the trend of decreased physical activity
and increase caloric intake, these external factors are
playing out on a genetic background to determine body
mass and susceptibility to obesity-related disease [4].
From the point of view of Evolutionary Genetics, it has
been hypothesized that there are some “thrifty genes”
that have been fixed in our genome for thousands of
years to prevent hunger, cold and calamities which hinder
feeding [13]. On the contrary, PPAR γ2 is an “unthrifty”
gene which has been shown to play an important role in
adipocyte differentiation, regulation of lipid metabolism
and sensitivity to insulin [7, 14, 15]. It has a protective ef-
fect against type 2 diabetes mellitus, and is associated to
obesity [14–16]. Data on the genetic epidemiology of
PPAR γ2 are very scare in populations of African ancestry.
This study aimed to investigate the frequency of the
proline to alanine substitution in the human PPAR γ2
gene and its association with obesity and T2DM in a
Cameroonian population. We found that the Ala allele
was completely absent in our study population, and the
Pro allele was fixed. The frequencies of the Ala vary
widely across ethnic populations. A typical black africans
population (Berba, African Bantu) shows no Ala12 allele
[17], whereas Ethiopian African population (Amhara) [17],
African American population (African ancestry on
Southwest USA) [18] and Oriental populations (Japanese,
Singapore Chinese, Han Chinese and Koreans) exhibit a
small Ala12 frequency [19–22]. Typical Far East Asian
populations and North African Caucasoids (Tunisians)
and Middle East Caucasoids (Qataris) show also a Ala12
low frequency [23, 24]. North Indian Sikhs have a high
Ala12 mutation frequency [25], as well as Europeans and
Amerindians [13, 26, 27]. Our findings are therefore con-
sistent with data from the literature which show that;
overall, black africans tend to show low or null Ala12
allele frequencies, while most other populations have a
significant frequency, particularly European Caucasoids.
These genetic epidemiologic patterns may be explained by
the fact that the Pro12 allele seems to be the wild allele
which must have occurred before modern humans left
Africa [14], while the Ala 12 allele must have occurred
in Caucasoids later on [14]. The variability in Ala 12
frequencies in Caucasians and Caucasoids may have
Table 1 Characteristics of obese patients and controls
Parameters Cases (n = 62) Controls (n = 60) p value
Age (years) 43 (11) 34 (12) <0.001
BMI (Kg/m2) 34.22 (4.62) 22.10 (1.70) <0.001
WHR 0.86 (0.07) 0.81 (0.06) <0.001
FPG (mg/dL) 96.81 (11.74) 92.03 (11.08) 0.027
SBP (mmHg) 131.13 (20.05) 116.98 (16.45) <0.001
DBP (mmHg) 80.53 (10.90) 70.77 (10.97) <0.001
T-C (mg/L) 190.5 (35.89) 180.68 (26.85) 0.040
TG (mg/dL) 135.79 (19.47) 131.81 (18.26) 0.247
HDL-C (mg/dL) 49.02 (7.89) 47.89 (5.37) 0.360
LDL-C (mg/dL) 114.84 (33.29) 106.46 (25.02) 0.119
AI 3.93 (0.68) 3.80 (0.62) 0.293
Data are expressed as mean (standard deviation)
FPG Fasting Plasma Glucose, SBP Systolic Blood Pressure, DBP Diastolic Blood
Pressure, HDL-C high density lipoprotein cholesterol, LDL-C low density
lipoprotein cholesterol, TG triglycerides, AI Atherogenic
index = total cholesterol/HDL-cholesterol
Table 2 Characteristics of the study population (T2DM status)
Parameters (n = 60) Controls (n = 60) p value
Age (years) 60 (20) 50 (12) <0.001
BMI (Kg/m2) 29.08 (5.74) 29 (4.76) 0.602
WHR 0.95 (0.08) 0.87 (0.07) <0.001
FPG (g/L) 1.78 (0.77) 0.92 (0.09) <0.001
SBP (mmHg) 137 (24) 138 (25) 0.775
DBP (mmHg) 79 (12) 85 (14) 0.034
T-C (g/L) 1.65 (0.23) 1.97 (0.39) <0.001
TG (g/L) 1.42 (0.29) 1.49 (0.27) 0.171
HDL-C (g/L) 0.49 (0.10) 0.51 (0.6) 0.274
LDL-C (g/L) 0.88 (0.21) 1.16 (0.36) <0.001
AI 2.31 (0.68) 1.86 (0.56) <0.00 1
Data are expressed as mean (standard deviation)
FPG Fasting Plasma Glucose, SBP Systolic Blood Pressure, DBP Diastolic Blood
Pressure, HDL-C high density lipoprotein cholesterol, LDL-C low density
lipoprotein cholesterol, TG triglycerides, AI Atherogenic
index = total cholesterol/HDL-cholesterol
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been due to evolutionary fitness forces pertaining to
feeding and metabolic adaptation.
Conclusion
This study suggests that PPAR-γ2 Pro12Ala mutation is
not associated with the development of obesity and
T2DM in the Cameroonian population. Our findings are
consistent with existing data which show no Ala12 allele
in typical black africans populations.
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